Studies of depression-related states in animal models of parkinsonism

Journal of Parkinson's Disease

Volumn 2, Issue 2, 2012, Pages 87-106

  Schintu, Nicoletta ^a   Zhang, Xiaoqun ^a   Svenningsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

anhedonia; dopamine; neurogenesis; Parkinson's disease; serotonin

Indexed keywords

1 METHYL 4 PHENYLTETRAHYDROPIRIDINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; GLUTAMIC ACID; INDUSTRIAL TOXIC SUBSTANCE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NORADRENALIN; OXIDOPAMINE; RESERPINE; ROTENONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL BEHAVIOR; ANIMAL MODEL; BRAIN DEPTH STIMULATION; CHRONIC MILD UNPREDICTABLE STRESS; DEPRESSION; DISEASE MODEL; FORCED SWIMMING TEST; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRACRANIAL SELF STIMULATION; KINESIOTHERAPY; LEARNED HELPLESSNESS; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NOVELTY INDUCED HYPOPHAGIA; NOVELTY SUPPRESSED FEEDING; OLFACTORY BULBECTOMY; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; REVIEW; RODENT; SOCIAL DEFEAT; SUCROSE PREFERENCE; TAIL SUSPENSION TEST; TREATMENT RESPONSE;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; PARKINSON DISEASE;

EID: 84864697183     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2012-12076     Document Type: Review

References (233)

1. Bower JH, Maraganore DM, McDonnell SK, & Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology, 52, 1214-1220.
2. Brooks SP, & Dunnett SB (2009) Tests to assess motor phenotype in mice: A user's guide. Nat Rev Neurosci, 10, 519-529.
3. Meredith GE, & Kang UJ (2006) Behavioral models of Parkinson's disease in rodents: A new look at an old problem. Mov Disord, 21, 1595-1606.
4. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211.
5. Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, & Svenningsson P (2012) Depression in Parkinson disease- epidemiology, mechanisms and management. Nat Rev Neurol, 8(1), 35-47.
6. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, & Rocca WA (2000) Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study. Mov Disord, 15, 669-677.
7. Cummings JL (1992) Depression and Parkinson's disease: A review. Am J Psychiatry, 149, 443-454.
8. Klein A, Metz GA, Papazoglou A, & Nikkhah G (2007) Differential effects on forelimb grasping behavior induced by fetal dopaminergic grafts in hemiparkinsonian rats. Neurobiol Dis, 27, 24-35.
9. Pinna A, Pontis S, Borsini F, & Morelli M (2007) Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse, 61, 606-614.
10. Schintu N, Frau L, Ibba M, Garau A, Carboni E, & Carta AR (2009) Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res, 16, 127-139.
11. Nestler EJ, & Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci, 13, 1161-1169.
12. Porsolt RD, Le Pichon M, & Jalfre M (1977) Depression: A new animal model sensitive to antidepressant treatments. Nature, 266, 730-732.
13. Pollak DD, Rey CE, & Monje FJ (2010) Rodent models in depression research: Classical strategies and newdirections. Ann Med, 42, 252-264.
14. Pollak DD, Monje FJ, Zuckerman L, Denny CA, DrewMR, &Kandel ER (2008) An animal model of a behavioral intervention for depression. Neuron, 60, 149-161.
15. Detke MJ, Rickels M, & Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl), 121, 66-72.
16. Steru L, Chermat R, Thierry B, & Simon P (1985) The tail suspension test:Anewmethod for screening antidepressants in mice. Psychopharmacology (Berl), 85, 367-370.
17. Cryan JF, Markou A, & Lucki I (2002) Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci, 23, 238-245.
18. Liu X, & Gershenfeld HK (2001) Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiatry, 49, 575-581.
19. Dulawa SC, Holick KA, Gundersen B, & Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology, 29, 1321-1330.
20. Dulawa SC, & Hen R (2005) Recent advances in animal models of chronic antidepressant effects: The noveltyinduced hypophagia test. Neurosci Biobehav Rev, 29, 771-783.
21. Reus V (2008) Mental disorders. In Harrison's Principles of Internal Medicine (Fauci, A., ed), McGraw-Hill Medical, pp. 2710-2723.
22. Jayatissa MN, Bisgaard C, Tingstrom A, Papp M, & Wiborg O (2006) Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology, 31, 2395-2404.
23. Slattery DA, Markou A, & Cryan JF (2007) Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl), 190, 555-568.
24. Moreau JL, Jenck F, Martin JR, Mortas P, & Haefely WE (1992) Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol, 2, 43-49.
25. Sherman AD, Sacquitne JL, & Petty F (1982) Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav, 16, 449-454.
26. Willner P (2005) Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology, 52, 90-110.
27. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, & Nestler EJ (2006) Essential role ofBDNFin the mesolimbic dopamine pathway in social defeat stress. Science, 311, 864-868.
28. Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, Laplant Q, Graham A, Lutter M, Lagace DC, Ghose S, Reister R, Tannous P, Green TA, Neve RL, Chakravarty S, Kumar A, Eisch AJ, Self DW, Lee FS, Tamminga CA, Cooper DC, Gershenfeld HK, & Nestler EJ (2007) Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell, 131, 391-404.
29. Song C, & Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev, 29, 627-647.
30. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol, 5, 107-110.
31. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C,&Takahashi RN (2008) Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience, 156, 830-840.
32. Lee CS, Sauer H,&Bjorklund A (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience, 72, 641-653.
33. Branchi I, D'Andrea I, Armida M, Cassano T, Pezzola A, Potenza RL, Morgese MG, Popoli P, & Alleva E (2008) Nonmotor symptoms in Parkinson's disease: Investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res, 86, 2050-2061.
34. Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, & Bishop C (2011) Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment. Neurosci Biobehav Rev, 35, 556-564.
35. Zhang X, Egeland M, & Svenningsson P (2011) Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology (Berl), 218, 621-634.
36. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R,&VitalMA(2010) Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry, 34, 1104-1114.
37. Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T, Morgenstern R, Kupsch A, & Juckel G (2007) Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res, 184, 133-141.
38. Dunnett SB,&LelosM(2010) Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Prog Brain Res, 184, 35-51.
39. Arai N, Misugi K, Goshima Y, & Misu Y (1990) Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res, 515, 57-63.
40. Fredriksson A, Eriksson P, & Archer T (1997) MPTPinduced deficits in motor activity: Neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J Neural Transm, 104, 579-592.
41. Willis GL, & Donnan GA (1987) Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res, 402, 269-274.
42. Nishi K, Kondo T, & Narabayashi H (1991) Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa. Neurosci Lett, 123, 244-247.
43. Mori A, Ohashi S, Nakai M, Moriizumi T, & Mitsumoto Y (2005) Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res, 51, 265-274.
44. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki DM, Smith A, Petzinger GM, & Jakowec MW (2008) Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis, 32, 319-327.
45. Petroske E, Meredith GE, Callen S, Totterdell S, & Lau YS (2001) Mouse model of Parkinsonism: A comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience, 106, 589-601.
46. Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, & Chesselet MF (2004) Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol, 187, 418-429.
47. Klein A, Gidyk DC, Shriner AM, Colwell KL, Tatton NA, Tatton WG, & Metz GA (2011) Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: A cautionary note. Behav Brain Res, 222, 33-42.
48. Menzaghi F, Whelan KT, Risbrough VB, Rao TS, & Lloyd GK (1997) Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther, 280, 393-401.
49. Dawson L, Chadha A, Megalou M, & Duty S (2000) The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol, 129, 541-546.
50. Carlsson A, Lindqvist M, & Magnusson T (1957) 3,4- Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 180, 1200.
51. Skalisz LL, Beijamini V, Joca SL, Vital MA, Da Cunha C, & Andreatini R (2002) Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association. Prog Neuropsychopharmacol Biol Psychiatry, 26, 879-883.
52. Bolandghamat S, Moghimi A,&IranshahiM(2011) Effects of ethanolic extract of pine needles (Pinus eldarica Medw.) on reserpine-induced depression-like behavior in maleWistar rats. Pharmacogn Mag, 7, 248-253.
53. Corti O, Lesage S, & Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev, 91, 1161-1218.
54. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
55. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, & Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
56. Chesselet MF (2008) In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease? Exp Neurol, 209, 22-27.
57. Oksman M, Tanila H, & Yavich L (2006) Brain reward in the absence of alpha-synuclein. Neuroreport, 17, 1191-1194.
58. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, & Bjorklund A (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: A new primate model of Parkinson's disease. Proc Natl Acad Sci U S A, 100, 2884-2889.
59. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, & Shen J (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem, 278, 43628-43635.
60. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, & Garcia de Yebenes J (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet, 12, 2277-2291.
61. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, & Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem, 279, 18614-18622.
62. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, Dawson VL, & Dawson TM (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A, 101, 10744-10749.
63. Perez FA, & Palmiter RD (2005) Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A, 102, 2174-2179.
64. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, BogdanovM, Przedborski S, BealMF, Burke RE, & Li C (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci, 12, 826-828.
65. Mooslehner KA, Chan PM, Xu W, Liu L, Smadja C, Humby T, Allen ND, Wilkinson LS, & Emson PC (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism. Mol Cell Biol, 21, 5321-5331.
66. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, & Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci, 27, 8138-8148.
67. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, & Miller GW (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci, 29, 8103-8113.
68. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, & Edwards RH (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron, 19, 1271-1283.
69. Fukui M, Rodriguiz RM, Zhou J, Jiang SX, Phillips LE, Caron MG, & Wetsel WC (2007) Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci, 27, 10520-10529.
70. Galvan A, & Wichmann T (2008) Pathophysiology of parkinsonism. Clin Neurophysiol, 119, 1459-1474.
71. Halliday GM, Macdonald V, & Henderson JM (2005) A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain, 128, 2272-2280.
72. Calabresi P, De Murtas M, & Bernardi G (1997) The neostriatum beyond the motor function: Experimental and clinical evidence. Neuroscience, 78, 39-60.
73. Sasaki-Adams DM, & Kelley AE (2001) Serotonindopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology, 25, 440-452.
74. Del Tredici K, Rub U, De Vos RA, Bohl JR, & Braak H (2002) Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol, 61, 413-426.
75. Zhou FM,Wilson C,&Dani JA(2003) Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist, 9, 23-36.
76. Roth RH,&Elsworth JD (1995) Biochemical pharmacology of midbrain dopaminergic neurons. In The Forth Generation of progress (F. Bloom, D. Kupfer, eds.), LippincottWilliam & Wilkins, New York, pp. 227-243.
77. Chen Z,&Skolnick P (2007) Triple uptake inhibitors: Therapeutic potential in depression and beyond. Expert Opin Investig Drugs, 16, 1365-1377.
78. Dunlop BW, & Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry, 64, 327-337.
79. Remy P, Doder M, Lees A, Turjanski N, & Brooks D (2005) Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain, 128, 1314-1322.
80. Carboni E, Tanda GL, Frau R, & Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem, 55, 1067-1070.
81. Willner P (1997) The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol, 12(Suppl 3), S7-S14.
82. Willner P, Lappas S, Cheeta S, & Muscat R (1994) Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl), 115, 454-462.
83. Navailles S, Benazzouz A, Bioulac B, Gross C, & De Deurwaerdere P (2010) High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci, 30, 2356-2364.
84. Radad K, Gille G, & Rausch WD (2005) Short review on dopamine agonists: Insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep, 57, 701-712.
85. PierceyMF,Walker EL, Feldpausch DL,&Camacho-Ochoa M(1996) High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Lett, 219, 138-140.
86. Maj J, Rogoz Z, Skuza G,&KolodziejczykK(1997) Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm, 104, 525-533.
87. Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, & Olivier B (2009) Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol, 616, 134-140.
88. Frisina PG, Haroutunian V, & Libow LS (2009) The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord, 15, 144-148.
89. Becker T, Becker G, Seufert J, Hofmann E, LangeKW, Naumann M, Lindner A, Reichmann H, Riederer P, Beckmann H, & Reiners K (1997) Parkinson's disease and depression: Evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry, 63, 590-596.
90. Paulus W, & Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol, 50, 743-755.
91. Mayeux R, Stern Y, Cote L, & Williams JB (1984) Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology, 34, 642-646.
92. Kostic VS, Djuricic BM, Covickovic-Sternic N, Bumbasirevic L, Nikolic M, & Mrsulja BB (1987) Depression and Parkinson's disease: Possible role of serotonergic mechanisms. J Neurol, 234, 94-96.
93. Kuhn J, & HuffW(2010)Will deep-brain stimulation be as successful in major depression as it has been in Parkinson's disease? Expert Rev Neurother, 10, 1363-1365.
94. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, & Schwarting RK (2000) MPTP susceptibility in the mouse: Behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet, 30, 171-182.
95. Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Launay JM, Cohen-Salmon C, & Hirsch EC (2003) Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis, 14, 218-228.
96. Casas S, Garcia S, Cabrera R, Nanfaro F, Escudero C, & Yunes R (2011) Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats. Pharmacol Biochem Behav, 99, 614-618.
97. Borah A, & Mohanakumar KP (2007) Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol, 27, 985-996.
98. Maruyama W, Naoi M, Takahashi A, Watanabe H, Konagaya Y, Mokuno K, Hasegawa S, & Nakahara D (1992) The mechanism of perturbation in monoamine metabolism by Ldopa therapy: In vivo and in vitro studies. J Neural Transm Gen Sect, 90, 183-197.
99. Navailles S, Bioulac B, Gross C, & De Deurwaerdere P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis, 38, 136-143.
100. Savitz J, Lucki I, & Drevets WC (2009) 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol, 88, 17-31.
101. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, & Seyfried CA (2004) Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm, 111, 113-126.
102. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, & Holsboer F (2000) Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry, 47, 305-313.
103. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, & Drevets WC (2007) Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry, 64, 193-200.
104. Pfleiderer B, Michael N, Erfurth A, Ohrmann P, Hohmann U, Wolgast M, Fiebich M, Arolt V, & HeindelW(2003) Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res, 122, 185-192.
105. Soiza-Reilly M, & Commons KG (2011) Glutamatergic drive of the dorsal raphe nucleus. J Chem Neuroanat, 41, 247-255.
106. Sanacora G, Zarate CA, Krystal JH,&ManjiHK(2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov, 7, 426-437.
107. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, & Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 63, 856-864.
108. KoikeH, Iijima M,&Chaki S (2011) Involvement ofAMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res, 224, 107-111.
109. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, & Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 475, 91-95.
110. Luscher B, Shen Q, & Sahir N (2011) The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry, 16, 383-406.
111. Kalueff AV,&Nutt DJ (2007) Role of GABA in anxiety and depression. Depress Anxiety, 24, 495-517.
112. Earnheart JC, Schweizer C, Crestani F, Iwasato T, Itohara S, Mohler H, & Luscher B (2007) GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J Neurosci, 27, 3845-3854.
113. Shen Q, Lal R, Luellen BA, Earnheart JC, Andrews AM, & Luscher B (2010) gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biol Psychiatry, 68, 512-520.
114. Maguire J, & Mody I (2008) GABA(A)R plasticity during pregnancy: Relevance to postpartum depression. Neuron, 59, 207-213.
115. Graef S, Schonknecht P, Sabri O,&HegerlU(2011) Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings. Psychopharmacology (Berl), 215, 205-229.
116. Furey ML, & Drevets WC (2006) Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry, 63, 1121-1129.
117. Overstreet DH, Friedman E, Mathe AA, & Yadid G (2005) The Flinders Sensitive Line rat: A selectively bred putative animal model of depression. Neurosci Biobehav Rev, 29, 739-759.
118. Drevets WC, & Furey ML (2010) Replication of scopolamine's antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial. Biol Psychiatry, 67, 432-438.
119. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, &PicciottoMR(2004) High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry, 56, 657-664.
120. Mineur YS, Somenzi O, & Picciotto MR (2007) Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology, 52, 1256-1262.
121. Rabenstein RL, Caldarone BJ, & Picciotto MR (2006) The nicotinic antagonist mecamylamine has antidepressantlike effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl), 189, 395-401.
122. Turner JR, Castellano LM, & Blendy JA (2010) Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. J Pharmacol Exp Ther, 334, 665-672.
123. Rollema H, Hajos M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, &Williams KE (2009) Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol, 78, 813-824.
124. Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA, & Picciotto MR (2009) Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol, 605, 114-116.
125. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr, Janowsky DS, & Kling MA (1999) Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl), 142, 193-199.
126. Schapira AH (2007) Treatment options in the modern management of Parkinson disease. Arch Neurol, 64, 1083-1088.
127. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, Lobsien D, Barthel H, Brust P, Gertz HJ, Sabri O, & Schwarz J (2009) Reduced alpha4beta2.-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry, 66, 866-877.
128. Fredholm BB, Chen JF, Cunha RA, Svenningsson P,&Vaugeois JM (2005) Adenosine and brain function. Int Rev Neurobiol, 63, 191-270.
129. Olah ME, & Stiles GL (2000) The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther, 85, 55-75.
130. Svenningsson P, Le Moine C, Fisone G, & Fredholm BB (1999) Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol, 59, 355-396.
131. Fenu S, Pinna A, Ongini E, & Morelli M (1997) Adenosine A2A receptor antagonism potentiates LDOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol, 321, 143-147.
132. Pinna A, Fenu S, & Morelli M (2001) Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse, 39, 233-238.
133. Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, &MorelliM(2007) Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats. Eur J Pharmacol, 566, 94-102.
134. Ikeda K, Kurokawa M, Aoyama S, & Kuwana Y (2002) Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem, 80, 262-270.
135. Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, & Morelli M (2009) Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem, 111, 1478-1489.
136. Minor TR, Chang WC, & Winslow JL (1994) Stress and adenosine: I. Effect of methylxanthine and amphetamine stimulants on learned helplessness in rats. Behav Neurosci, 108, 254-264.
137. Woodson JC, Minor TR, & Job RF (1998) Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats. Behav Neurosci, 112, 399-409.
138. Kulkarni SK, & Mehta AK (1985) Purine nucleoside-mediated immobility in mice: Reversal by antidepressants. Psychopharmacology (Berl), 85, 460-463.
139. ElYacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, & Vaugeois JM (2001) Adenosine A2A receptor antagonists are potential antidepressants: Evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol, 134, 68-77.
140. Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, Cohen-Williams ME, Higgins GA, Impagnatiello F, Nicolussi E, Parra LE, Foster C, Zhai Y, Neustadt BR, Stamford AW, Parker EM, Reggiani A, & Hunter JC (2009) Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1- piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazol o[4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther, 330, 294-303.
141. Krishnan V, & Nestler EJ (2008) The molecular neurobiology of depression. Nature, 455, 894-902.
142. McEwen BS (2008) Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol, 583, 174-185.
143. Arborelius L, Owens MJ, Plotsky PM, & Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol, 160, 1-12.
144. Holsboer F (2001) Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy. J Affect Disord, 62, 77-91.
145. Noble RE (2005) Depression in women. Metabolism, 54, 49-52.
146. Bekku N, Yoshimura H, & Araki H (2006) Factors producing a menopausal depressive-like state in mice following ovariectomy. Psychopharmacology (Berl), 187, 170-180.
147. Beckley EH, & Finn DA (2007) Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. Pharmacol Biochem Behav, 87, 412-419.
148. George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, & Post RM (1994) CSF neuroactive steroids in affective disorders: Pregnenolone, progesterone, and DBI. Biol Psychiatry, 35, 775-780.
149. Urani A, Roman FJ, Phan VL, Su TP, & Maurice T (2001) The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther, 298, 1269-1279.
150. Serra M, Pisu MG, Muggironi M, Parodo V, Papi G, Sari R, Dazzi L, Spiga F, Purdy RH, & Biggio G (2001) Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmacology (Berl), 158, 48-54.
151. Marx CE, Shampine LJ, Khisti RT, Trost WT, Bradford DW, Grobin AC, Massing MW, Madison RD, Butterfield MI, Lieberman JA, & Morrow AL (2006) Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: Implications for therapeutic actions. Pharmacol Biochem Behav, 84, 609-617.
152. Uzunov DP, Cooper TB, Costa E, & Guidotti A (1996) Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci U S A, 93, 12599-12604.
153. KhistiRT, ChopdeCT,&Jain SP (2000) Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav, 67, 137-143.
154. Conner JM, Lauterborn JC, Yan Q, Gall CM, & Varon S (1997) Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: Evidence for anterograde axonal transport. J Neurosci, 17, 2295-2313.
155. Huang EJ, & Reichardt LF (2001) Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci, 24, 677-736.
156. HowellsDW, Porritt MJ,Wong JY, Batchelor PE, Kalnins R, Hughes AJ, & Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol, 166, 127-135.
157. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, & Nagatsu T (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett, 270, 45-48.
158. Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, & Raisman-Vozari R (1999) Reduced expression of brainderived neurotrophic factor
159. Kohno R, Sawada H, Kawamoto Y, Uemura K, Shibasaki H, & Shimohama S (2004) BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochem Biophys Res Commun, 318, 113-118.
160. Porritt MJ, Batchelor PE, & Howells DW (2005) Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol, 192, 226-234.
161. Baquet ZC, Bickford PC, & Jones KR (2005) Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci, 25, 6251-6259.
162. Fumagalli F, Racagni G, Colombo E, & Riva MA (2003) BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatry, 8, 898-899.
163. Baydyuk M, Nguyen MT, & Xu B (2011) Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp Neurol, 228, 118-125.
164. Murer MG, Yan Q, & Raisman-Vozari R (2001) Brainderived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol, 63, 71-124.
165. Levivier M, Przedborski S, Bencsics C, & Kang UJ (1995) Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci, 15, 7810-7820.
166. Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J,&Burns LH (1995) Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med, 1, 1189-1194.
167. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, & Pandey GN (2003) Altered gene expression of brainderived neurotrophic factor and receptor tyrosine kinaseBin postmortem brain of suicide subjects. Arch Gen Psychiatry, 60, 804-815.
168. Brunoni AR, Lopes M, & Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol, 11, 1169-1180.
169. Siuciak JA, Lewis DR, Wiegand SJ, & Lindsay RM (1997) Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav, 56, 131-137.
170. ShirayamaY, ChenAC, Nakagawa S, Russell DS,&Duman RS (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci, 22, 3251-3261.
171. Warner-Schmidt JL,&Duman RS (2007)VEGFis an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A, 104, 4647-4652.
172. Greene J, Banasr M, Lee B, Warner-Schmidt J, & Duman RS (2009) Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: Pharmacological and cellular characterization. Neuropsychopharmacology, 34, 2459-2468.
173. Tian YY, Tang CJ, Wang JN, Feng Y, Chen XW, Wang L, Qiao X, & Sun SG (2007) Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adenoassociated viral vectors. Neurosci Lett, 421, 239-244.
174. Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, & Cenci MA (2011) Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: Implications for the development of dyskinesia. Brain, 134, 2339-2357.
175. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, PetersonDA,&Gage FH (1998) Neurogenesis in the adult human hippocampus. Nat Med, 4, 1313-1317.
176. Kempermann G,&GageFH(2002) Genetic determinants of adult hippocampal neurogenesis correlate with acquisition, but not probe trial performance, in the water maze task. Eur J Neurosci, 16, 129-136.
177. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, Drew M, Craig DA, Guiard BP, Guilloux JP, Artymyshyn RP, Gardier AM, Gerald C, Antonijevic IA, Leonardo ED,&HenR(2009) Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron, 62, 479-493.
178. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, & Hirsch EC (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci, 7, 726-735.
179. Navailles S, Hof PR, & Schmauss C (2008) Antidepressant drug-induced stimulation of mouse hippocampal neurogenesis is age-dependent and altered by early life stress. J Comp Neurol, 509, 372-381.
180. Freundlieb N, Francois C, Tande D, Oertel WH, Hirsch EC, & Hoglinger GU (2006) Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci, 26, 2321-2325.
181. Winner B, Desplats P, Hagl C, Klucken J, Aigner R, Ploetz S, Laemke J, Karl A, Aigner L, Masliah E, Buerger E, & Winkler J (2009) Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol, 219, 543-552.
182. Winner B, Lie DC, Rockenstein E, Aigner R, Aigner L, Masliah E, Kuhn HG, &Winkler J (2004) Human wild-type alpha-synuclein impairs neurogenesis. J Neuropathol Exp Neurol, 63, 1155-1166.
183. Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, Patrick C, Winner B, Winkler J, & Masliah E (2008) Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci, 28, 4250-4260.
184. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Horsten S, Schmidt T, Boy J, Kuhn M, Nguyen HP, Teismann P, Schulz JB, Neumann M, Pichler BJ, Reischl G, Holzmann C, Schmitt I, Bornemann A, Kuhn W, Zimmermann F, Servadio A, & Riess O (2008) Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci, 28, 2471-2484.
185. Winner B, Rockenstein E, Lie DC, Aigner R, Mante M, Bogdahn U, Couillard-Despres S, Masliah E,&Winkler J (2008) Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol Aging, 29, 913-925.
186. Lennington JB, Pope S, Goodheart AE, Drozdowicz L, Daniels SB, Salamone JD, & Conover JC (2011) Midbrain dopamine neurons associated with reward processing innervate the neurogenic subventricular zone. J Neurosci, 31, 13078-13087.
187. van den Berge SA, van Strien ME,Korecka JA, Dijkstra AA, Sluijs JA, Kooijman L, Eggers R, De Filippis L, Vescovi AL, Verhaagen J, van de Berg WD, & Hol EM (2011) The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain. Brain, 134, 3249-3263.
188. Winner B, Vogt-Weisenhorn DM, Lie CD, Blumcke I, & Winkler J (2009) Cellular repair strategies in Parkinson's disease. Ther Adv Neurol Disord, 2, 51-60.
189. Santarelli L, SaxeM, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, & Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301, 805-809.
190. Radley JJ, & Jacobs BL (2002) 5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus. Brain Res, 955, 264-267.
191. Banasr M, Hery M, Printemps R, & Daszuta A (2004) Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology, 29, 450-460.
192. Gao HM, Hong JS, Zhang W, & Liu B (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci, 22, 782-790.
193. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, & Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci, 15, 991-998.
194. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, & Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem, 81, 1285-1297.
195. Castano A, Herrera AJ, Cano J, & Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem, 70, 1584-1592.
196. Herrera AJ, Castano A, Venero JL, Cano J, & Machado A (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis, 7, 429-447.
197. Allan SM, & Rothwell NJ (2001) Cytokines and acute neurodegeneration. Nat Rev Neurosci, 2, 734-744.
198. Sriram K, Miller DB,&O'Callaghan JP (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factoralpha. J Neurochem, 96, 706-718.
199. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, & Hong JS (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett, 329, 354-358.
200. Sairam K, Saravanan KS, Banerjee R, & Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res, 966, 245-252.
201. Teismann P, & Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse, 39, 167-174.
202. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, & Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A, 98, 14669-14674.
203. He Y, Appel S, & Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res, 909, 187-193.
204. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, & Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci, 22, 1763-1771.
205. Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, & Venero JL (2004) Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis, 16, 190-201.
206. Maes M (1993) A review on the acute phase response in major depression. Rev Neurosci, 4, 407-416.
207. Maes M (2008) The cytokine hypothesis of depression: Inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett, 29, 287-291.
208. Maes M, Smith R, & Scharpe S (1995) The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology, 20, 111-116.
209. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, & Maj M (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis, 24, 27-53.
210. Miller AH, Maletic V, & Raison CL (2009) Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry, 65, 732-741.
211. De La Garza R, 2nd (2005) Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: Focus on anhedonia. Neurosci Biobehav Rev, 29, 761-770.
212. Dunn AJ, & Swiergiel AH (2005) Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav, 81, 688-693.
213. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, & Yirmiya R (2008) Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry, 13, 717-728.
214. Dobos N, de Vries EF, Kema IP, Patas K, Prins M, Nijholt IM, Dierckx RA, Korf J, den Boer JA, Luiten PG, Eisel UL (2011) The role of indoleamine 2, 3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis, 28(4), 905-915.
215. Zhu CB, Lindler KM, OwensAW,Daws LC, Blakely RD,& HewlettWA(2010) Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology, 35, 2510-2520.
216. Barr AM, Song C, Sawada K, Young CE, Honer WG, & Phillips AG (2003) Tolerance to the anhedonic effects of lipopolysaccharide is associated with changes in syntaxin immunoreactivity in the nucleus accumbens. Int J Neuropsychopharmacol, 6, 23-34.
217. Connor TJ, Song C, Leonard BE, Anisman H, & Merali Z (1999) Stressor-induced alterations in serotonergic activity in an animal model of depression. Neuroreport, 10, 523-528.
218. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, Weihe E, & Weidenfeld J (2001) Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology, 24, 531-544.
219. Castanon N, Bluthe RM, & Dantzer R (2001) Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl), 154, 50-60.
220. Song C, & Wang H (2011) Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry, 35, 760-768.
221. Vallieres L, Campbell IL, Gage FH,&Sawchenko PE(2002) Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci, 22, 486-492.
222. Monje ML, Toda H, & Palmer TD (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science, 302, 1760-1765.
223. Battista D, Ferrari CC, Gage FH, & Pitossi FJ (2006) Neurogenic niche modulation by activated microglia: Transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci, 23, 83-93.
224. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, & Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med, 339, 1105-1111.
225. Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, & Stacy M (2011) Impulse control disorders in Parkinson disease: A multicenter case-control study. Ann Neurol, 69, 986-996.
226. Tan SK, Hartung H, Sharp T, & Temel Y (2011) Serotonindependent depression in Parkinson's disease: A role for the subthalamic nucleus? Neuropharmacology, 61, 387-399.
227. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, & Kennedy SH (2005) Deep brain stimulation for treatment-resistant depression. Neuron, 45, 651-660.
228. Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, & Schlaepfer TE (2010) Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry, 67, 110-116.
229. Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK, & Jakowec MW (2004) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res, 77, 378-390.
230. Petzinger GM,Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vuckovic M, Fisher BE, Togasaki DM, & Jakowec MW (2007) Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci, 27, 5291-5300.
231. Tillerson JL, Caudle WM, Reveron ME, & Miller GW (2003) Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience, 119, 899-911.
232. Duman CH, Schlesinger L, Russell DS,&Duman RS (2008) Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res, 1199, 148-158.
233. Gorton LM, Vuckovic MG, Vertelkina N, Petzinger GM, JakowecMW, &Wood RI (2010) Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav Brain Res, 213, 253-262.